Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...
SHA: 600276
Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer
The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...
Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...
Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...
Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...
Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...
Hengrui Medicine’s Pyrotinib Filing Accepted for Review by NMPA
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its supplementary market filing...
Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review
China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276)...
Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Hengrui Medicine to Incentivize Employees with Share Distribution
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...
Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial
China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...
Hengrui Medicine’s Pyrotinib Combo Meets Endpoints in HER2+ Breast Cancer Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its tyrosine kinase inhibitor (TKI) pyrotinib,...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...
Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...
Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...